PlainPharmaWatch

CMS Open Payments · Program Year 2024

Sequence LifeScience, Inc

Sequence LifeScience, Inc reported $194,500.00 across General Payments, Research, and Ownership to 64 physicians and teaching hospitals across 64 transactions.

See the rankings → How this is sourced
$194.5K
All-tracks total
64
Transactions
64
Recipients
#1008
of 1,925 companies

Sequence LifeScience, Inc reported $194,500.00 across all CMS Open Payments tracks (General + Research + Ownership) to 64 physicians and teaching hospitals in Program Year 2024 - ranking #1008 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $194,500.00, averaging $3.0K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer sequence-lifescience-inc Sequence LifeScience, Inc

$194.5K · #1008/1,925 · 0.0% industry · PY2024

  • TOT $194.5K
  • RANK #1008
  • SHARE 0.0%
  • TXN 64
  • RCP 64
  • CAT 1
  • GEN $194.5K
  • TOP1 84.6%
  • PY 2024

Volume peers

Nearest volume peer: Channel Medsystems, Inc. ($194.3K)

Sequence LifeScience, Inc (t…$194.5KChannel Medsystems, Inc.$194.3KMedicem Inc.$194.1KPulpdent Corporation$194.0KNanoFuse Biologics LLC$193.9K
All-tracks payment totals near Sequence LifeScience, Inc (CMS Open Payments PY2024)

Sequence LifeScience, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Sequence LifeScience, Inc

Averaging $3.0K per transaction and $3.0K per recipient, Sequence LifeScience, Inc's Program Year 2024 total comes to $194,500.00 across 64 transactions and 64 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1008 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 1-category general-payment breakdown below at $194.5K (100.0% of General Payments, 64 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Sequence LifeScience, Inc made 1 types of general payments. "Consulting Fee" is the largest category at $194.5K, 100.0% of General Payments.

How Sequence LifeScience, Inc divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$194.5K
Payment Type Amount Transactions
Consulting Fee $194.5K 64

Recipient Concentration in General Payments

The five largest recipient relationships account for $194,500.00 (100.0%) of $194,500.00 in this company's General Payments records across 2 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Sequence LifeScience, Inc

The five named recipients with the highest reported General Payments from this company

Michael Bauer$164.5KWalter Strash$30.0K
  1. 1

    Michael Bauer

    $164,500.00 across 52 reported transactions

  2. 2

    Walter Strash

    $30,000.00 across 12 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Sequence LifeScience, Inc's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sequence LifeScience, Inc.

Aesculap Biologics, LLC

HHI 7394

Teleflex Medical Incorporated

HHI 7395

Elekta, Inc.

HHI 7371

Nanovis LLC

HHI 7351

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Sequence LifeScience, Inc.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Sequence LifeScience, Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.